As Group C at the Africa Cup of Nations enters its third and final matchday, Nigeria's commanding start is reflected in the Super Eagles progressing as winners regardless of the results in the ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Recursion Pharmaceuticals has designated its top research executive, Najat Khan, to succeed co-founder Chris Gibson as president and chief executive of the clinical-stage biotechnology company, ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...

RangeError: Maximum call stack size exceeded File "/home/nextjs/apps/web/.next/server/chunks/5316.js", line 1, in c File "/home/nextjs/apps/web/.next/server/chunks ...

Shares of Recursion Pharmaceuticals rose Tuesday morning after the company said slashing its workforce by 20% will extend its cash runway to the end of 2027. Shares were trading more than 10% higher ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...